Search

Objective: The main objective of this study was to evaluate the efficacy of tamsulosin or mirabegron on ureteral stent‐related symptoms. Patients and methods: This was a prospective, randomized, controlled, and single‐blinded study. In total, 180 patients who had undergone ureterolithotripsy and ureteral stent insertion were included. Patients were randomly divided into three groups as follows: Group 1 was the control group taking placebo; group 2 was administered tamsulosin (0.4 mg) once a day; and group 3 received mirabegron (50 mg) once a day. The Turkish version of the ureteral stent symptom questionnaire was filled out after 4 weeks. Results: After excluding patients who were lost to follow‐up, 161 patients were included in the final analysis. Analgesic usage doses were lower in the tamsulosin (5.1 ± 1.8) and mirabegron (4.5 ± 1.4) groups than in the control group (5.9 ± 2.1; P <.001). The urinary symptoms score was lower in tamsulosin group than it was in the control group (22.1 vs 27.8; P =.001); however, the other scores (body pain, general health, work performance, sexual matters, and other problems) were similar between the groups. Conclusions: Tamsulosin improves only urinary symptoms due to the ureteral stent and decreases the need for analgesics. Mirabegron has no effect on ureteral stent‐related symptoms, but it decreases analgesic need. [ABSTRACT FROM AUTHOR]

Objective: We aimed to evaluate the efficacy of tamsulosin in the treatment of lower urinary tract symptoms (LUTS) in patients under active surveillance (AS) for low-risk prostate cancer (Pca). Materials and Methods: Patients who underwent prostate biopsy between 2010 and 2014 were evaluated prospectively. Inclusion criteria for AS were PSA level below 10 ng/mL, a tumor in a maximum of two cores, a tumor core percentage below 50%, a clinical stage ≤ T2a and a Gleason score ≤6. Patients under AS with LUTS were included in the study group and patients with benign pathology results with LUTS were included in the control group. International prostate symptom score (IPSS) and uroflowmetry test were used to evaluate LUTS. The maximum flow rate (Qmax) was recorded. All patients received tamsulosin 0.4 mg once daily in a modified-release formulation (Flomax MR®, Astellas, Japan). Transurethral resection prostatectomy (TUR-P) was performed when surgical treatment was necessary for obstruction despite tamsulosin treatment. Results: The study included a total of 91 patients, 41 patients in the AS group and 50 patients in the control group. Patients were assessed after six months. There was a 30% reduction in IPSS in the AS group and 24.5% in the control group (p=0.591). Qmax increased by 20.4% in the AS group and by 20% in the control group (p=0.985). The need for TUR-P was similar between the two groups (14.6% vs 20%, p=0.503) during three-year follow-up. Conclusion: Tamsulosin can be used safely and with high efficacy for LUTS in patients under AS for low-risk Pca. The improvement in IPSS and Qmax, and the need for surgical treatment were similar to the control group. [ABSTRACT FROM AUTHOR]